FluoGuide develops surgical solutions that are expected to reduce suffering for the patient and increase the likelihood of cure as well as reducing costs for the health care system.

New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

New exchange: Nasdaq First North

Board of directors

Shomit Ghose - Member of the board FluoGuide

Shomit Ghose

Member of the board

Shomit A. Ghose is a Managing Director and General Partner at ONSET Ventures, a Silicon Valley venture fund, where he has been active since 2001. He has served on multiple boards within ONSET’s portfolio, and previously also served as Chief Executive Officer of Truviso, where he also sat on the Board. He is a seasoned technology executive and a venture capitalist with technology operating experience. In addition to his time as an investor, he has 19 years of executive experience at high-tech companies in the Silicon Valley. Shomit Ghose specializes in the information technology sector with a focus on software, networking and infrastructure. He has been instrumental in several IPOs. Shomit Ghose holds a degree in Computer Science from the University of California Berkeley.

Micaela Sjökvist - Member of the board FluoGuide

Micaela Sjökvist

Member of the board

Micaela Sjökvist is Head of Investor Relations at Securitas AB, a public listed company active in the security sector. Sjökvist has over 20 years of experience within corporate communications, financial communications and investor relations in listed international companies. Previous experience includes operative roles at both the international PR consultancy company Grayling and Telia Sonera AB. Micaela Sjökivst holds a B.Sc in Economics and Business Administration from Uppsala University.

Peter Mørch Eriksen - Chairman of the board FluoGuide

Peter Mørch Eriksen

Chairman of the board

Peter Mørch Eriksen is the CEO in BioPorto A/S. Peter Mørch Eriksen has more than 20 years of experience within medtech/life science both in Denmark and abroad. Prior to joining BioPorto A/S, Peter Mørch Eriksen was the CEO of Sense A/S and before this, he held positions as Vice President of Medtronic in both the USA and Denmark. From these positions Peter Mørch Eriksen brings extensive experience in creating growth, restructuring and funding in technology intensive and complex companies. Peter Mørch Eriksen has an accounting background supplemented with courses in management. In addition to being CEO of BioPorto A/S, Peter Mørch Eriksen chairs the board of MTIC, is a board member at Nervex A/S, member of Lund University Advisory Board, and Director of PMEconsult ApS. He also serves on the Medical Device and Diagnostics Advisory Committee of Cincinnati Children’s Hospital Medical Center in Ohio, US. Peter Mørch Eriksen is an independent Board Member.

Andreas Kjaer - member of the board FluoGuide

Andreas Kjaer

member of the board

Andreas Kjaer, is an MD, PhD, DMSc and professor at the University of Copenhagen and chief physician at Rigshospitalet, the National University Hospital of Denmark. His research is focused on molecular imaging with PET and PET/MRI in cancer and cardiovascular disease and his achievements include development of several new tracers that have reached first-in-humans clinical use. He is the holder of an ERC Advanced Grant, has published more than 400 peer-review articles and has received numerous prestigious scientific awards over the years. Andreas Kjaer also has an MBA from Copenhagen Business School.

Mats Thorèn - member of the board FluoGuide

Mats Thorèn

member of the board

Mats Thorén has 25 years of experience from the financial markets, where he has worked in the Healthcare both as an equity analyst and in corporate finance. For the past seventeen years, Mats Thorén has been a Healthcare investment professional. He has worked with Nalka Life Science AB and MedCap AB and now manages his own company, Vixco Capital, with a focus on investments. He currently serves on the boards of Xbrane BioPharma AB (Stockholm Smallcap), Arcoma AB (Stockholm First North) and Herantis Pharma Oy (Stockholm and Helsinki First North). He has previous board experience from C-Rad AB (Stockholm First North), as well as Cellartis AB, Duocort AB, MIP Technologies AB and several other private companies. Mats Thorén has studied at the Stockholm School of Economics focusing on Accounting and Financial Economics as well as studies in medicine at the Karolinska Institute in Stockholm.